SGLT2 inhibitors (SGLT2i) improve heart failure outcomes, and GLP-1 receptor agonists (GLP-1 RA) confer cardiometabolic benefit. However, outcomes after GLP-1 RA initiation according to background SGLT2i use remain uncertain.
Using TriNetX, we compared GLP-1 RA initiation in patients with HFpEF and type 2 di...
Vikash Jaiswal, M. Banach, Asmita Gera et al.· Archives of Medical Science· 0 citations
Introduction/Background:
Hypertensive disorders of pregnancy remain a major cause of maternal and fetal morbidity, and aspirin is widely used for preeclampsia risk reduction. However, the optimal aspirin dose in real-world pregnancy care remains uncertain, and comparative effectiveness data evaluating higher-dose ve...
K. Soni, M. Hanif, Hritvik Jain et al.· Circulation· 0 citations
In patients with NSTEMI and stable HF, early PCI was associated with higher risk of adverse cardiovascular outcomes, warranting further investigation in this understudied subgroup.
M. Hanif, Vivek Bhat, Anthony Mufarreh et al.· Catheterization and cardiova...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.